LaurenH
-
Posts
795 -
Joined
-
Last visited
-
Days Won
27
Content Type
Downloads
Store
Profiles
Forums
Gallery
Blogs
Events
Posts posted by LaurenH
-
-
Hi, Allyn,
Welcome to LCSC. I am sorry to hear about your wife's diagnosis. You have come to a good place to connect with other caregivers and lung cancer survivors. Our members have a wealth of experience navigating a lung cancer diagnosis and treatment. If you're comfortable, could you tell us a bit more about your wife's diagnosis? Then we may be able to connect you with someone who has a similar diagnosis. We are here for you.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, ViviAnn,
Thank you for making an introductory post! Welcome to LCSC. I'm glad to see you've been able to connect with Susan. Please continue to join in the conversations in the discussion boards and feel free to post questions. If you'd like more information about LUNGevity's support resources and programs, I would be happy to connect with you.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Karen,
Welcome to LCSC. I'm glad to see you've already connected with some of our members. This is a great community to find hope and help while navigating a lung cancer diagnosis and treatment. Here is a link to an overview on how to use the site. Please continue to explore the discussion boards, read the blogs, and join the conversations which resonate with you. Feel free to ask questions and please let me know if you'd like additional information about LUNGevity's resources and support programs. We are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Lori,
Welcome to LCSC. We are glad you've joined this community. I hope that here, like in the ALKies group, you can make many meaningful connections and find both hope and helpful information. Please feel free to explore the discussion boards and join in on the conversations. We also have member blogs that you can check out. I would be happy to provide you with educational resources or information about LUNGevity's support programs, should you desire them. Please continue to post updates. We are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
For many cancer patients genomic testing provides a unique opportunity to identify the most promising drug therapy options based on genetic indicators identified through the test results. Patient Advocate Foundation (PAF) is pleased to offer theGenomic Testing Support CareLine which is designed to provide assistance to patients who have completed a genomic test on clinical samples collected during their cancer or other genomics-guided diagnosis, or who are encountering barriers accessing and finalizing that process. Patients who are having trouble accessing treatment that has been identified by the testing are also able to receive assistance to reduce some of the financial or insurance barriers that may exist.
The CareLine is staffed by expert case managers who offer high touch, personalized assistance to patients, caregivers and providers who are utilizing genomic tests to aid in treatment decisions, helping with both the denial of drugs with indicators based on test results and the denial of any genomic test regardless of cancer type. This represents a comprehensive approach to patient support and allows PAF to actively engage in the delivery of appeals assistance from the initial genomic testing phase through the actual delivery of prescribed care.
Those in need of assistance can reach the Genomic Testing Support CareLine toll free at (866) 460-1928 or through the web based portal at genomicsupport.pafcareline.org. From diagnosis to survivorship, this free service is here for patients and their families as they navigate treatment and healthcare based on genomic testing.Genomic Testing Support CareLine Details:
- Two ways to initiate a request for support: phone and online secure portal
- No financial requirements to qualify for assistance and all services are free of charge for patients and their families
- Assistance for patients who have already undergone genomic testing/profiling and now wish to proceed with accessing an off label drug
- Assistance with insurance challenges relative to accessing the prescribed genomic test
- Assistance with clinical trials research and access
- Assistance with prior authorization or predetermination requests
“Each cancer journey is unique and PAF is grateful to have an opportunity to offer this exciting new program that adds a unique layer of personalized support to complement the care that patients are receiving from their doctors and treatment teams each day,” says Beth Moore, Executive Vice President of the Patient Advocate Foundation.
PAF case managers are on call to answer questions and provide direct assistance to cancer patients facing challenges accessing genomic testing and/or prescribed care based on test results. The Genomic Testing Support CareLine can be accessed toll free at (866) 460-1928 or by visiting genomicsupport.pafcareline.org. -
Hi, vinnpal,
Welcome to LCSC. I am glad you've been able to connect with several of our members and that their posts have given you some of the information you need. Here is a link to LUNGevity's website where you can find more questions to ask your medical team.
I am happy to provide you with additional resources or more information about LUNGevity's support programs. In the meantime, please continue to explore the discussion boards, join the conversations, and ask questions. We are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
So glad to hear it! Thank you for the update! I hope his follow up appointments go well. We'll be thinking of you and your family. Please keep us posted!
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Sherry,
Welcome to LCSC. I'm sorry you've been through so much lately. We're glad that you found this community. It is a great place to connect with others who are navigating a lung cancer diagnosis and to share experiences. Please feel free to explore the discussion boards and join in on any of the conversations which resonate with you. When you have more information about your diagnosis, this community is a good place to ask questions. I am also happy to give you some information on LUNGevity's support programs. In the meantime, know that we are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Thank you both for providing us with that feedback! We want to make sure people have a realistic idea of how long the study will take.
Lauren
--
Digital Community Manager
LUNGevity Founation -
-
The research team at Tulane University is conducting an online survey of individuals with cancer histories. We are particularly interested in individuals with a history of lung cancer.
The survey takes about 10 minutes and asks about people's beliefs about their health and healthcare, emotions and behaviors, and health history. We hope that the study will build knowledge that can help individuals with cancer to be more satisfied with their care.
Here is a link to the survey
his study has been approved by LUNGevity Foundation.
-
-
Hi, Susan,
I'm glad you're on a break from treatment! I hope you get good scans! I always appreciate the wit and wisdom in your posts.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Cristina,
You and your husband are in our hearts. How are you both doing? Could you give us more details about your husband's targeted therapy? Then we may be able to give you more information or connect you to someone who has been on that treatment.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Pearl,
We're thinking of you and hoping you have some answers! Please post an update when you can.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, RayJ,
We're thinking of you. Hope your surgery went well! Please post an update when you can.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Jeffrey,
I'm glad you're out of the hospital. How did the move go?
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, CJ,
Welcome to LCSC. I'm sorry that you've been through so much. We're glad you've joined this community. We are here for you if you have questions or if you're looking for information/resources.
Please keep us posted on your biopsy results!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Thank you for sharing this, Isunique! Where is your 5K? I love the message on your running shirt. How is your training going?
Lauren
--
Digital Community Manager
LUNGevity Foundation -
FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
South San Francisco, CA -- August 2, 2017 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. The FDA will make a decision on approval by November 30, 2017.
“Phase III results showed Alecensa reduced the risk of disease worsening by more than half compared to the current standard of care and lowered the risk of tumors spreading to or growing in the brain by more than 80 percent,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are working closely with the FDA to bring this medicine as an initial treatment for people with ALK-positive NSCLC as soon as possible.”
This sNDA submission for Alecensa is based on results from the Phase III ALEX and Phase III J-ALEX studies. A Priority Review designation is granted to proposed medicines that, if approved, the FDA has determined to have the potential to provide a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease.
Alecensa received Breakthrough Therapy Designation from the FDA in September 2016 for the treatment of adults with advanced ALK-positive NSCLC who have not received prior treatment with an ALK inhibitor. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible. Breakthrough Therapy Designation was granted on the basis of the Phase III J-ALEX trial.
Alecensa was granted accelerated approval by the FDA in December 2015 for the treatment of people with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. The ALEX study is part of the company’s commitment in the U.S. to convert the current accelerated approval of Alecensa in people with ALK-positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib to a full approval as an initial treatment.
Read the full press release here.
-
-
Hi, MichelleC,
Welcome to LCSC. I am happy to read that your husband is responding well to treatment. Please continue to post and share updates! And of course, feel free to ask questions. I am glad to see that you've already connected with some of our members. In addition to the message boards, we also have some great member blogs, including Tom's!
You've already received some great advice, and here is a link to some caregiving tips from LUNGevity's website. Please let me know if you'd like more information on any particular topic and I can help connect you with resources.
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Hi, Pegi,
Welcome to LCSC. You'll find many other caregivers in this community, as well as survivors like Tom, who can share the patient's perspective. This is a great place to make connections and ask questions of others navigating a similar diagnosis. If you would like to learn more about LUNGevity's resources and programs for caregivers, I'm happy to share more information with you.
If you're on Twitter, we host a monthly chat for caregivers. Our next chat is coming up next Wednesday, August 2, at 8PM EDT. Topics change from month to month. Next week, we'll be discussing legal issues for caregivers. Our host Danielle, is a LUNGevity volunteer, and caregiver to her parents (one has lc, one has a chronic health issue). She is extremely knowledgeable and is an active voice in our community, especially on social media.
We are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation -
Dave,
I'm very happy to read your update! I hope that you continue to gain your energy and your appetite back. We'll be thinking of you going into your upcoming scan and hoping for more positive results! You're a very positive presence in this community and we continue to be here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation
New here
in INTRODUCE YOURSELF!
Posted
Hi, Daughter74,
Welcome to LCSC. I am sorry to hear about your dad's diagnosis. I am glad that you've found this community. This is a great place to connect with others whose lives have been impacted by lung cancer.
LUNGevity's Lung Cancer 101 website has a lot of information about small cell lung cancer (SCLC). We also offer support services and resources for survivors and caregivers. Please let me know if you'd like more information about any of LUNGevity's resources and programs and I will be happy to help. We are here for you!
With gratitude,
Lauren
--
Digital Community Manager
LUNGevity Foundation